Showing results (121-130 of 181) with videos related to

Sort By:
Pageof 19
Kidney International Reports|December 11, 2020
Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO TrialPaolo Raggi, Antonio Bellasi, Smeeta Sinha, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 9, 2021
Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis: An Analysis of the Randomized, Placebo-Controlled CaLIPSO StudyDavid A Bushinsky, Paolo Raggi, Jordi Bover, et al.
Plos One|July 16, 2015
Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid LeukemiaUmayal Sivagnanalingam, Marlene Balys, Allison Eberhardt, et al.
Pituitary|August 13, 2016
Geographic variation in cost of care for pituitary tumor surgeryCharles C Lee, Kristopher T Kimmell, Amy Lalonde, et al.
Plos One|July 14, 2012
Bone marrow-derived matrix metalloproteinase-9 is associated with fibrous adhesion formation after murine flexor tendon injuryAlayna E Loiselle, Benjamin J Frisch, Matthew Wolenski, et al.
American Journal of Nephrology|December 20, 2015
Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing ReceptorDavid A Bushinsky, Geoffrey A Block, Kevin J Martin, et al.
ESC Heart Failure|May 17, 2018
Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DNBertram Pitt, George L Bakris, Matthew R Weir, et al.
ESC Heart Failure|January 26, 2018
Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney diseaseBertram Pitt, David A Bushinsky, Dalane W Kitzman, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 13, 2019
One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidismDavid A Bushinsky, Glenn M Chertow, Sunfa Cheng, et al.
Kidney International|September 17, 2015
Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemiaDavid A Bushinsky, Gordon H Williams, Bertram Pitt, et al.
Pageof 19